SUBSCRIBE
SUBSCRIBE

MAIA Biotechnology

IN THE PRESS
Press Releases
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
June 25, 2026
 · 
6 min read
Press Releases
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
June 18, 2026
 · 
6 min read
Press Releases
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
June 10, 2026
 · 
7 min read
Press Releases
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
June 4, 2026
 · 
6 min read
Press Releases
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
June 3, 2026
 · 
7 min read
Press Releases
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
June 3, 2026
 · 
4 min read
Press Releases
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
June 1, 2026
 · 
6 min read
Press Releases
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
April 16, 2026
 · 
7 min read
Press Releases
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
April 8, 2026
 · 
6 min read
Press Releases
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
March 31, 2026
 · 
6 min read
Load More
JOBS